Annovis Bio is down -16.8%, or -$1.56 to $7.72.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio falls -8.5%
- Annovis Bio Shares Surge on Positive Parkinson’s Study Data
- Annovis Bio’s buntanetap shows efficacy in Phase 3 Parkinson’s study
- Annovis Bio files provisional patent for manufacturing process of buntanetap
- Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap